Palisades Hudson Asset Management’s AbbVie ABBV Stock Holding History

Palisades Hudson Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$600K	Sell	2,384 -897	-27%	-$193K	0.21%	49
2026 Q1	$713K	Hold	3,281	–	–	0.28%	43
2025 Q4	$749K	Hold	3,281	–	–	0.29%	43
2025 Q3	$761K	Hold	3,281	–	–	0.28%	44
2025 Q2	$609K	Sell	3,281 -263	-7%	-$48.9K	0.24%	49
2025 Q1	$742K	Sell	3,544 -196	-5%	-$38.1K	0.34%	39
2024 Q4	$665K	Sell	3,740 -6	-0.2%	-$1.1K	0.28%	42
2024 Q3	$740K	Sell	3,746 -397	-10%	-$74.1K	0.31%	40
2024 Q2	$711K	Hold	4,143	–	–	0.33%	40
2024 Q1	$755K	Hold	4,143	–	–	0.34%	39
2023 Q4	$642K	Sell	4,143 -3	-0.1%	-$437	0.31%	44
2023 Q3	$618K	Hold	4,146	–	–	0.34%	38
2023 Q2	$558K	Hold	4,146	–	–	0.29%	45
2023 Q1	$661K	Hold	4,146	–	–	0.35%	37
2022 Q4	$670K	Sell	4,146 -1	-0%	-$153	0.37%	34
2022 Q3	$556K	Sell	4,147 -459	-10%	-$65.9K	0.34%	36
2022 Q2	$705K	Buy	4,606 +460	+11%	+$70.3K	0.4%	33
2022 Q1	$672K	Buy	4,146 +24	+0.6%	+$3.49K	0.31%	38
2021 Q4	$558K	Hold	4,122	–	–	0.24%	54
2021 Q3	$445K	Hold	4,122	–	–	0.2%	62
2021 Q2	$464K	Hold	4,122	–	–	0.21%	57
2021 Q1	$446K	Sell	4,122 -224	-5%	-$24K	0.21%	57
2020 Q4	$465K	Buy	4,346 +200	+5%	+$19.2K	0.24%	53
2020 Q3	$363K	Hold	4,146	–	–	0.23%	62
2020 Q2	$407K	Buy	4,146 +220	+6%	+$19.4K	0.28%	47
2020 Q1	$299K	Hold	3,926	–	–	0.25%	57
2019 Q4	$348K	Hold	3,926	–	–	0.22%	62
2019 Q3	$297K	Hold	3,926	–	–	0.21%	66
2019 Q2	$285K	Hold	3,926	–	–	0.2%	71
2019 Q1	$316K	Sell	3,926 -936	-19%	-$76.6K	0.2%	65
2018 Q4	$448K	Hold	4,862	–	–	0.26%	47
2018 Q3	$460K	Sell	4,862 -14	-0.3%	-$1.33K	0.24%	51
2018 Q2	$452K	Hold	4,876	–	–	0.24%	50
2018 Q1	$462K	Hold	4,876	–	–	0.25%	44
2017 Q4	$472K	Sell	4,876 -1,050	-18%	-$99K	0.26%	43
2017 Q3	$527K	Hold	5,926	–	–	0.3%	38
2017 Q2	$430K	Hold	5,926	–	–	0.25%	50
2017 Q1	$386K	Hold	5,926	–	–	0.25%	48
2016 Q4	$371K	Hold	5,926	–	–	0.23%	49
2016 Q3	$374K	Hold	5,926	–	–	0.29%	41
2016 Q2	$367K	Hold	5,926	–	–	0.3%	44
2016 Q1	$338K	Hold	5,926	–	–	0.27%	55
2015 Q4	$351K	Hold	5,926	–	–	0.3%	48
2015 Q3	$322K	Hold	5,926	–	–	0.29%	48
2015 Q2	$399K	Hold	5,926	–	–	0.34%	38
2015 Q1	$347K	Hold	5,926	–	–	0.27%	52
2014 Q4	$388K	Hold	5,926	–	–	0.3%	46
2014 Q3	$342K	Hold	5,926	–	–	0.28%	52
2014 Q2	$334K	Sell	5,926 -104	-2%	-$5.46K	0.28%	40
2014 Q1	$310K	Sell	6,030 -114	-2%	-$5.76K	0.27%	39
2013 Q4	$324K	Hold	6,144	–	–	0.27%	40
2013 Q3	$275K	Hold	6,144	–	–	0.25%	44
2013 Q2	$254K	Buy	+6,144	New	+$269K	0.24%	46

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Palisades Hudson Asset Management's ABBV Position: Q2 2026 in Review

Palisades Hudson Asset Management reduced its AbbVie (ABBV) stake by 27% in Q2 2026, selling an estimated $193K and leaving 2,384 shares worth $600K. The position accounts for 0.21% of the portfolio, ranked #49.

Palisades Hudson Asset Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $761K in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Palisades Hudson Asset Management held 2,384 shares of AbbVie worth $600K as of Q2 2026.
Palisades Hudson Asset Management sold 897 AbbVie shares in Q2 2026, an estimated $193K.
AbbVie made up 0.21% of Palisades Hudson Asset Management's portfolio in Q2 2026, its #49 holding.
Palisades Hudson Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Palisades Hudson Asset Management's AbbVie position peaked at $761K in Q3 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Palisades Hudson Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.